Teva Pharmaceuticals
TEVA
539 hedge funds and large institutions have $11.9B invested in Teva Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 202 increasing their positions, 164 reducing their positions, and 69 closing their positions.
89% more call options, than puts
Call options by funds: $589M | Put options by funds: $312M
23% more repeat investments, than reductions
Existing positions increased: 202 | Existing positions reduced: 164
9% more capital invested
Capital invested by funds: $11B → $11.9B (+$977M)
0.53% more ownership
Funds ownership: 62.33% → 62.86% (+0.53%)
4% less funds holding
Funds holding: 560 → 539 (-21)
12% less funds holding in top 10
Funds holding in top 10: 26 → 23 (-3)
22% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$183M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$166M |
| 3 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$150M |
| 4 |
SC
Soundwatch Capital
Rowayton,
Connecticut
|
+$138M |
| 5 |
PC
PointState Capital
New York
|
+$90.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$397M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$87.6M |
| 3 |
Millennium Management
New York
|
-$70.9M |
| 4 |
Morgan Stanley
New York
|
-$70.7M |
| 5 |
Citigroup
New York
|
-$47.7M |
TEVA Hedge Fund Activity: Q2 2025 in Review
539 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2025, worth a combined $11.9B — up 8.9% from $11B a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of TEVA and 54 opened new positions — a net loss of 15 holders — while 164 trimmed existing stakes and 202 added.
The largest buyer was Harel Insurance Investments & Financial Services, adding an estimated $183M. The largest seller was Fidelity Investments, cutting an estimated $397M.
- 539 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2025, down from 560 in Q1 2025.
- Funds reported $11.9B of Teva Pharmaceuticals stock for Q2 2025, up 8.9% quarter-over-quarter.
- 54 funds opened new Teva Pharmaceuticals positions in Q2 2025 and 69 closed out, a net change of -15 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2025 was Harel Insurance Investments & Financial Services, an estimated $183M added.
- The largest Teva Pharmaceuticals seller in Q2 2025 was Fidelity Investments, an estimated $397M sold.
Based on aggregated 13F filings for Q2 2025.